Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Abiraterone + Prednisone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Abiraterone | Zytiga | CB7630 | Hormone - Anti-androgens 47 | Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov). |
Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03016741 | FDA approved | Enzalutamide Abiraterone + Prednisone | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | Unknown status | USA | 0 |
NCT03419234 | Phase II | Abiraterone + Prednisone Abiraterone + Cabazitaxel + Prednisone | Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel | Active, not recruiting | USA | 1 |
NCT02218606 | Phase II | Cabazitaxel Abiraterone + Prednisone | Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer | Completed | USA | 0 |
NCT04291664 | Phase I | Abiraterone + Prednisone DST-2970 + Prednisone | PK and Dose Escalation and Expansion Study of DST-2970 | Active, not recruiting | USA | 0 |
NCT04691804 | Phase III | Abiraterone + Fluzoparib + Prednisone Abiraterone + Prednisone | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | GBR | FRA | ESP | BEL | AUS | 7 |
NCT03827473 | Phase II | Abiraterone + Prednisone Docetaxel | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC) | Terminated | USA | 0 |
NCT03649841 | Phase II | Abiraterone + Prednisone Abiraterone + Prednisone + Radiotherapy | Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate Cancer | Terminated | USA | 0 |
NCT03834519 | Phase III | Abiraterone + Prednisone Enzalutamide Olaparib + Pembrolizumab | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 11 |
NCT04812366 | Phase II | Abiraterone + Apalutamide + Prednisone Apalutamide Abiraterone + Prednisone Apalutamide + Atezolizumab Abiraterone + Docetaxel + Prednisone Abiraterone + Niraparib + Prednisone | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS) | Recruiting | USA | CAN | 0 |
NCT01688492 | Phase Ib/II | Abiraterone + Prednisone Ipilimumab | Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01715285 | Phase III | Abiraterone + Prednisone | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | Completed | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 26 |
NCT04497844 | Phase III | Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 24 |
NCT05288166 | Phase III | Abiraterone + Prednisone Abemaciclib + Abiraterone + Prednisone | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 15 |
NCT05276492 | Phase I | Abiraterone + Prednisone | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. | Recruiting | USA | 0 |
NCT03565835 | Phase II | Abiraterone + Prednisone | Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT05204927 | Phase III | Abiraterone + Enzalutamide lutetium Lu 177 vipivotide tetraxetan Abiraterone + Prednisone | Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | ITA | FRA | ESP | 0 |
NCT02429193 | Phase II | Enzalutamide Abiraterone + Prednisone | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P) | Completed | CAN | 0 |
NCT04647526 | Phase III | Abiraterone + Dexamethasone Abiraterone + Prednisone Enzalutamide PNT2002 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) | Active, not recruiting | USA | GBR | FRA | CAN | 2 |
NCT04887506 | Phase III | Abiraterone + Prednisone Prednisone + TAVT-45 | TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | Completed | USA | GBR | FRA | ESP | 4 |
NCT03511196 | Phase I | Abiraterone + Prednisone Leuprolide Goserelin Triptorelin | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03748641 | Phase III | Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 20 |
NCT01576172 | Phase II | Abiraterone + Prednisone Abiraterone + Prednisone + Veliparib | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | 0 |
NCT03012321 | Phase II | Abiraterone + Olaparib + Prednisone Abiraterone + Prednisone Olaparib | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | Active, not recruiting | USA | 0 |
NCT04175431 | Phase II | Abiraterone + Prednisone | Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | Recruiting | USA | 0 |
NCT03706365 | Phase II | Abemaciclib + Abiraterone + Prednisone Abiraterone + Prednisone | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | Active, not recruiting | USA | GBR | FRA | ESP | DEU | AUS | 5 |
NCT03833921 | Phase II | Abiraterone + Prednisone | Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (APRE) | Recruiting | USA | 0 |
NCT01940276 | Phase II | Abiraterone + Prednisone | Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer | Completed | USA | 0 |
NCT04446117 | Phase III | Enzalutamide Atezolizumab + Cabozantinib Abiraterone + Prednisone | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 17 |